Teja Pharma Profile
Key Indicators
- Authorised Capital ₹ 7.00 M
as on 27-06-2024
- Paid Up Capital ₹ 7.00 M
as on 27-06-2024
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 2.18 Cr
as on 27-06-2024
- Satisfied Charges ₹ 3.86 Cr
as on 27-06-2024
- Revenue -45.68%
(FY 2018)
- Profit -16.51%
(FY 2018)
- Ebitda 6.60%
(FY 2018)
- Net Worth 4.88%
(FY 2018)
- Total Assets -2.23%
(FY 2018)
About Teja Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 7.00 M and a paid-up capital of Rs 7.00 M.
The company currently has active open charges totaling ₹2.18 Cr. The company has closed loans amounting to ₹3.86 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nangamangalam Vasantha and Nangamangalam Giridharan serve as directors at the Company.
- CIN/LLPIN
U51397TN2011PTC079341
- Company No.
079341
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2011
- Date of AGM
30 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Teja Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nangamangalam Vasantha  | Director | 26-Sep-2018 | Current |
| Nangamangalam Giridharan | Director | 27-Feb-2017 | Current |
Financial Performance and Corporate Structure Insights of Teja Pharma.
Teja Pharma Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 45.68% decrease. The company also saw a substantial fall in profitability, with a 16.51% decrease in profit. The company's net worth moved up by a moderate rise of 4.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Teja Pharma?
In 2018, Teja Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Udayam Pharmaceuticals Private LimitedActive 11 years 3 monthsNangamangalam Vasantha and Nangamangalam Giridharan are mutual person
- Annamalayar Medicals Private LimitedActive 18 years 6 months
Nangamangalam Giridharan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tamilnad Mercantile Bank Limited Creation Date: 31 Jan 2018 | ₹2.18 Cr | Open |
City Union Bank Limited Creation Date: 28 Apr 2016 | ₹1.33 Cr | Satisfied |
Icici Bank Limited Creation Date: 19 Aug 2015 | ₹1.33 Cr | Satisfied |
How Many Employees Work at Teja Pharma?
Unlock and access historical data on people associated with Teja Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Teja Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Teja Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
